Evolocumab & Inclisiran dual therapy for further LDL lowering in a very high cardiovascular risk Familial Hypercholesterolaemia patient with heterozygous gain of function PCSK9 mutation

被引：0
|
作者：
Gingell, R. [1 ]
Das, P. [2 ]
Teoh, Y. P. [3 ]
机构：
[1] Glan Clwyd Gen Hosp, All Wales Familial Hypercholesterolaemia Serv Nor, Bodelwyddan, Denbigh, Wales
[2] Glan Clwyd Gen Hosp, Dept Cardiol, Bodelwyddan, Denbigh, Wales
[3] Wrexham Maelor Hosp, Dept Chem Pathol & Metab Med, Wrexham, Wales
来源：
ATHEROSCLEROSIS PLUS | 2023年 / 54卷
关键词：
D O I：
10.1016/j.athplu.2023.07.020
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S4 / S5
页数：2
相关论文
共 16 条
  • [1] THERAPEUTIC LDL-C LOWERING WITH PCSK9 DIRECTED OLIGONUCLEOTIDE THERAPY (INCLISIRAN) IN A PATIENT WITH FAMILIAL HYPERLIPIDEMIA (FH) REFRACTORY TO PCSK-9 MONOCLONAL ANTIBODY (EVOLOCUMAB)
    Skove, Stephanie
    Anderson, Jeffrey L.
    Le, Viet T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2474 - 2474
  • [2] Impact of evolocumab, a PCSK9 inhibitor, withdrawing from regular ldl-apheresis therapy in patients with heterozygous familial hypercholesterolemia
    Kawashiri, M.
    Higashikata, T.
    Nohara, A.
    Nakanishi, C.
    Tada, H.
    Okada, H.
    Yamagishi, M.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1331 - 1331
  • [3] Prevalence, Clinical Characteristics and Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia Patients With Double-Heterozygous Mutation of LDLR and PCSK9 Gain-Of-Function Mutation
    Doi, Takahito
    Hori, Mika
    Harada-Shiba, Mariko
    Kataoka, Yu
    Nishikawa, Ryo
    Tsuda, Kosuke
    Nishimura, Kunihiro
    Ogura, Masatsune
    Noguchi, Teruo
    Yasuda, Satoshi
    CIRCULATION, 2018, 138
  • [4] EFFECT OF PCSK9 INHIBITION WITH EVOLOCUMAB ON THE CONCENTRATION AND COMPOSITION OF LDL SUBFRACTIONS IN HIGH-RISK PATIENTS WITH CARDIOVASCULAR DISEASE
    Scharnagl, H.
    Kannenkeril, D.
    Stojakovic, T.
    Silbernagel, G.
    Bosch, A.
    Maerz, W.
    Schmieder, R.
    ATHEROSCLEROSIS, 2023, 379 : S71 - S71
  • [5] Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?
    Vuorio, Alpo
    Watts, Gerald F.
    Kovanen, Petri T.
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1353 - 1356
  • [6] Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy
    Huang, Kui
    Wen, Xiao-Qin
    Ren, Ning
    Yang, Li
    Gao, Bo
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2021, 22 (02) : 461 - 467
  • [7] Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors
    Rallidis, Loukianos S.
    Liberopoulos, Evangelos N.
    Vlachopoulos, Charalambos
    Skoumas, Ioannis
    Kolovou, Genovefa
    Anastasiou, Georgia
    Dima, Ioanna
    Tousoulis, Dimitrios
    Iliodromitis, Efstathios
    ATHEROSCLEROSIS, 2020, 309 : 67 - 69
  • [8] POPULATION DOSE-RESPONSE MODELING OF INCLISIRAN, A NOVEL siRNA INHIBITOR TO PCSK9, IN PATIENTS AT HIGH CARDIOVASCULAR RISK WITH ELEVATED LDL CHOLESTEROL.
    Kathman, S.
    Bellibas, S. E.
    Kallend, D. G.
    Ray, K. K.
    Wheeler, J.
    Wijngaard, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S72 - S72
  • [9] The new LDL-C target <55 mg/dL is achieved by less than 40% of very high risk patients with familial hypercholesterolaemia despite receiving PCSK9 inhibitors: real world data
    Rallidis, L.
    Vlachopoulos, C.
    Liberopoulos, E.
    Skoumas, I
    Kiouri, E.
    Koutagiar, I
    Anastasiou, G.
    Kosmas, N.
    Tousoulis, D.
    Iliodromitis, E.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2999 - 2999
  • [10] Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus
    Kosmas, Constantine E.
    Sourlas, Andreas
    Bouza, Kyriaki V.
    DeJesus, Eddy
    Silverio, Delia
    Montan, Peter D.
    Guzman, Eliscer
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (07)
12